Pfizer to sell off Remicade biosim in EU to win Hospira deal nod; Sanofi prices Toujeo on par with Lantus in U.K.;

> Pfizer ($PFE) won E.U. approval for its $16 billion Hospira ($HSP) purchase after the company agreed to sell European rights to its biosimilar version of Remicade (infliximab). Report

> Sanofi ($SNY) priced Toujeo, its new longer-acting version of Lantus, on par with the older med in the U.K. in hopes of grabbing market share to withstand generic rivals. Report

> Over the long term, birth control pills actually protect against uterine cancer, contrary to fears that they could cause the disease, a new study found. Report

> AB Science has been studying its drug candidate masitinib in a wide swath of diseases, though it has only won approval to market the drug to treat cancer in dogs. Report

And Finally... A new analysis of anti-dementia drugs such as Eisai's Aricept found that the cholinesterase inhibitors can cause harmful weight loss. Report

Suggested Articles

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.

Bristol Myers Squibb and Exelixis will soon know whether their I-O/TKI combo gets a chance to challenge Merck and Pfizer's Keytruda-Inlyta regimen.